Table 2.
Total | Control group | EECP group | P value a | P value b | |||
---|---|---|---|---|---|---|---|
EECP initiated within 2 weeks | EECP initiated after 2 weeks | (t-test) | (ANOVA) | ||||
Eyes (n) | 76 | 39 | 37 | 8 | 29 | ||
BCVA | |||||||
Baseline | 0.87 ± 0.93 | 0.99 ± 1.14 | 0.74 ± 0.62 | 0.66 ± 0.48 | 0.76 ± 0.65 | 0.095 | 0.492 |
Month 2 | 0.79 ± 0.72 | 0.82 ± 0.68 | 0.76 ± 0.76 | 0.80 ± 0.52 | 0.75 ± 0.83 | 0.954 | 0.926 |
Change (2–0) | −0.07 ± 0.52 | −0.16 ± 0.59 | 0.02 ± 0.44 | 0.15 ± 0.25 | −0.01 ± 0.47 | 0.261 | 0.211 |
Month 6 | 0.75 ± 0.61 | 0.72 ± 0.51 | 0.77 ± 0.72 | 0.83 ± 0.92 | 0.67 ± 0.62 | 0.174 | 0.145 |
Change (6–0) | 0.01 ± 0.43 | − 0.02 ± 0.35 | 0.04 ± 0.51 | 0.21 ± 0.32 | − 0.05 ± 0.41 | 0.264 | 0.054 |
MD | |||||||
Baseline | −20.09 ± 9.27 | −19.26 ± 9.81 | −20.93 ± 8.77 | −18.97 ± 7.07 | −21.48 ± 9.24 | 0.239 | 0.602 |
Month 2 | − 19.28 ± 9.05 | −17.69 ± 9.41 | − 20.88 ± 8.50 | −18.76 ± 8.74 | − 21.77 ± 8.49 | 0.459 | 0.248 |
Change (2–0) | 0.81 ± 3.86 | 1.57 ± 4.38 | 0.04 ± 3.15 | 0.22 ± 2.48 | − 0.01 ± 3.35 | 0.287 | 0.244 |
Month 6 | −19.52 ± 9.09 | −19.21 ± 9.89 | −20.27 ± 7.24 | −16.75 ± 15.91 | −20.37 ± 5.71 | 0.096 | 0.798 |
Change (6–0) | 1.30 ± 4.15 | 2.28 ± 4.80 | 0.27 ± 3.15 | 1.37 ± 5.98 | 0.07 ± 4.15 | 0.443 | 0.290 |
RNFLT | |||||||
Baseline | 170.99 ± 76.65 | 175.61 ± 71.51 | 166.63 ± 82.01 | 155.42 ± 69.87 | 169.68 ± 85.65 | 0.140 | 0.801 |
Month 2 | 77.76 ± 29.40 | 81.44 ± 25.66 | 73.23 ± 33.48 | 82.00 ± 59.11 | 71.27 ± 27.31 | 0.835 | 0.511 |
Month 6 | 65.35 ± 20.24 | 65.63 ± 19.43 | 65.10 ± 21.42 | 57.67 ± 16.20 | 66.34 ± 22.30 | 0.600 | 0.796 |
EECP enhanced external counterpulsation, BCVA best-corrected visual acuity in LogMAR, MD mean deviation, RNFLT retinal nerve fiber layer thickness
aIndependent t-test comparing visual function between the EECP and control groups
bOne way ANOVA comparing the control group, EECP group with EECP initiated within 2 weeks and EECP group with EECP initiated after 2 weeks